Cargando…

Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice

BACKGROUND: The aim of this study was to assess the sociodemographic and clinical characteristics of patients with Alzheimer’s disease who switched from any oral cholinesterase inhibitor to rivastigmine patches. METHODS: An observational, retrospective, multicenter study was conducted in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Pousa, Secundino, Arranz, Francisco Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546803/ https://www.ncbi.nlm.nih.gov/pubmed/23341737 http://dx.doi.org/10.2147/PPA.S38719

Ejemplares similares

A prospective study on the use of rivastigmine transdermal patch in Alzheimer’s dementia in a routine clinical setting
por: Nazir, Ejaz, et al.
Publicado: (2010)

An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch
por: Grieco, T., et al.
Publicado: (2011)

The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease
por: Kim, Hyeyun, et al.
Publicado: (2016)

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
por: Han, Hyun Jeong, et al.
Publicado: (2011)

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review
por: Kurz, A, et al.
Publicado: (2009)

Preparation and Characterization of Rivastigmine Transdermal Patch Based on Chitosan Microparticles
por: Sadeghi, Mohsen, et al.
Publicado: (2016)

Third degree atrioventricular block associated with treatment with rivastigmine transdermal patch
por: Knudtzen, Fredrikke C., et al.
Publicado: (2013)

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
por: Seibert, Johannes, et al.
Publicado: (2012)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
por: dos Santos, Gustavo Alves Andrade, et al.
Publicado: (2011)

A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch
por: Vagenas, Vassileios, et al.
Publicado: (2015)

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study
por: Tsuno, Norifumi, et al.
Publicado: (2019)

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions
por: Adler, G, et al.
Publicado: (2014)

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
por: Moretti, Davide V., et al.
Publicado: (2014)

Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon(®) Transdermal Patch (Daily)- A Randomized Clinical Trial
por: Schurad, Bjoern, et al.
Publicado: (2022)

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease
por: Farlow, M.R., et al.
Publicado: (2011)

Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan
por: Ueda, Kengo, et al.
Publicado: (2019)

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study
por: Muñoz-Moreno, Jose A., et al.
Publicado: (2017)

Polymeric Microneedles for Transdermal Delivery of Rivastigmine: Design and Application in Skin Mimetic Model
por: Guimarães, Tânia M. T., et al.
Publicado: (2022)

Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease
por: Kim, Yong Kyun, et al.
Publicado: (2014)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

Adverse drug events affecting medication persistence with rivastigmine patch application
por: Osada, Takashi, et al.
Publicado: (2018)

The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
por: Yatawara, Chathuri, et al.
Publicado: (2021)

Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
por: Kim, Han-Joon, et al.
Publicado: (2011)

Improper Application of a Rivastigmine Patch to the Back of the Neck Induced Toxic Symptoms
por: Matsuzono, Kosuke, et al.
Publicado: (2023)

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life
por: Annicchiarico, Roberta, et al.
Publicado: (2007)

Formulation and Evaluation of Transdermal Patch of Repaglinide
por: Prajapati, Shailesh T., et al.
Publicado: (2011)

Pharmacokinetics of transdermal buprenorphine patch in the elderly
por: Al-Tawil, Nabil, et al.
Publicado: (2012)

Transdermal iontophoresis patch with reverse electrodialysis
por: Lee, Joon, et al.
Publicado: (2017)

Stimuli-responsive transdermal microneedle patches
por: Makvandi, Pooyan, et al.
Publicado: (2021)

Wearable patches for transdermal drug delivery
por: He, Jiahui, et al.
Publicado: (2023)

Two cases of Alzheimer’s disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
por: Kimura, Takemi, et al.
Publicado: (2013)

Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer’s Disease
por: Lefèvre, Gilbert, et al.
Publicado: (2016)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
por: Sakai, Shintaro, et al.
Publicado: (2021)

Formulation development and investigation of domperidone transdermal patches
por: Prabhu, Prabhakar, et al.
Publicado: (2011)

Fungal Endocarditis Secondary to Transdermal Fentanyl Patch
por: Casey, Bradley, et al.
Publicado: (2023)

Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
por: Ray, Balmiki, et al.
Publicado: (2020)

Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
por: Shimura, Hideki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ljjeijjtplh19pna92apdhmbbc